Very long-term survival of an older glioblastoma patient after treatment with cilengitide: a case report
Glioblastoma (GBM) is the most common malignant brain tumor. Less than 1% of patients survive longer than 10 years. A 77-year-old woman was diagnosed with MGMT-methylated GBM in 2009. The patient received cilengitide as part of the CENTRIC clinical trial in conjunction with standard radiation and ch...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-06-01
|
| Series: | CNS Oncology |
| Subjects: | |
| Online Access: | https://www.futuremedicine.com/doi/10.2217/cns-2022-0017 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Glioblastoma (GBM) is the most common malignant brain tumor. Less than 1% of patients survive longer than 10 years. A 77-year-old woman was diagnosed with MGMT-methylated GBM in 2009. The patient received cilengitide as part of the CENTRIC clinical trial in conjunction with standard radiation and chemotherapy. Though the study was halted in 2013, our patient received cilengitide until 2016 with no radiographic evidence of recurrence thus far. This is the oldest reported GBM patient with greater than 10-year survival. Her exceptional response may have been influenced by MGMT promoter methylation status and PTEN expression. |
|---|---|
| ISSN: | 2045-0907 2045-0915 |